ROTKREUZ, Switzerland and
SAN DIEGO, Jan. 29, 2015 /PRNewswire/ -- Roche (SIX:
RO, ROG; OTCQX: RHHBY) and Qualcomm Incorporated (NASDAQ: QCOM)
today announced that Qualcomm's subsidiary, Qualcomm Life, Inc.,
and Roche, a world leader in point-of-care diagnostics, have
entered into a strategic collaboration to improve remote monitoring
and management of chronic disease patients. Together, the companies
aim to advance chronic care management using connected therapy to
further improve therapy quality, increase convenience and drive
patient engagement in managing their health.
Roche will utilize Qualcomm Life's 2net Platform to seamlessly
and securely capture data from a patient's medical devices,
beginning with anticoagulation meters, and transmit it to Roche's
cloud-based back-end services. The 2net Platform is a secure
wireless solution that provides a simple and efficient way to
exchange relevant health information between chronic disease
patients and their care team or clinic to enable reduced therapy
complications and total cost of care.
As health care systems and providers are facing continual
pressure to deliver an improved quality of care at a lower cost,
patient satisfaction is becoming more important than ever.
Connected chronic care management and remote management solutions
can enhance patient care, enabling providers to asynchronously
communicate with their patients in a high-tech, high-touch model
minimizing risk of errors in result reporting. While many remote
patient monitoring and management solutions today require patients
to communicate results to their health care professionals in
manual, time-consuming and non-digitized channels, Qualcomm Life
and Roche are working together to deliver an improved process for
sharing health information between health care providers and their
patients.
"This collaboration marks a significant milestone for Roche as
we launch a new generation of point-of-care solutions that enable
healthcare professionals to better keep in touch remotely with
patients, whenever and wherever they are," says Jeremy Moss, senior vice president, Point of
Care at Roche Professional Diagnostics. "By combining Qualcomm
Life's leadership in powering connected health solutions with our
point-of-care expertise, we are taking an important step forward to
realize our connected care strategy; ultimately enabling physicians
to improve the overall quality of life for patients."
"We are thrilled to be working with a global industry leader in
diagnostics and excited by the positive impact our collaboration
with Roche can have on patient empowerment at the point-of-care,"
said Rick Valencia, senior vice
president and general manager, Qualcomm Life, Inc. "Together, Roche
and Qualcomm Life are committed to providing tools to patients and
their physicians and caregivers that empower greater coordination
to improve patient health."
About Roche
Headquartered in Basel,
Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and
diagnostics. Roche is the world's largest biotech company, with
truly differentiated medicines in oncology, immunology, infectious
diseases, ophthalmology and neuroscience. Roche is also the world
leader in in vitro diagnostics and tissue-based
cancer diagnostics, and a frontrunner in diabetes management.
Roche's personalised healthcare strategy aims at providing
medicines and diagnostics that enable tangible improvements in the
health, quality of life and survival of patients. Founded in 1896,
Roche has been making important contributions to global health for
more than a century. Twenty-four medicines developed by Roche are
included in the World Health Organization Model Lists of Essential
Medicines, among them life-saving antibiotics, antimalarials and
chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide,
invested 8.9 billion Swiss francs in
R&D and posted sales of 47.5 billion
Swiss francs. Genentech, in the
United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical,
Japan. For more information,
please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
About Qualcomm Incorporated
Qualcomm Incorporated (NASDAQ: QCOM) is a world leader in 3G, 4G
and next-generation wireless technologies. Qualcomm Incorporated
includes Qualcomm's licensing business, QTL, and the vast majority
of its patent portfolio. Qualcomm Technologies, Inc., a
wholly-owned subsidiary of Qualcomm Incorporated, operates, along
with its subsidiaries, substantially all of Qualcomm's engineering,
research and development functions, and substantially all of its
products and services businesses, including its semiconductor
business, QCT. For more than 25 years, Qualcomm ideas and
inventions have driven the evolution of digital communications,
linking people everywhere more closely to information,
entertainment and each other. For more information, visit
Qualcomm's website, OnQ blog, Twitter and Facebook pages.
Qualcomm and 2net are trademarks of Qualcomm Incorporated,
registered in the United States
and other countries. 2net is a product of Qualcomm Life, Inc.
All Qualcomm Incorporated trademarks are used with permission.
Qualcomm Contacts:
Emily Kilpatrick, Corporate
Communications
Phone: 1-858-845-5959
Email: corpcomm@qualcomm.com
Jamie Eisinger, Qualcomm Life,
Inc.
Phone: 1-858-845-1033
Email: jeisinge@qti.qualcomm.com
Warren Kneeshaw, Investor
Relations
Phone: 1-858-658-4813
Email: ir@qualcomm.com
Roche Contacts:
Jenna Eup, Communications US
Phone: 1-317-521-4477
Email: jenna.eup@roche.com
Daniel Fleiter, Public
Relations
Phone: +41 41 798 5990
Email: daniel.fleiter@roche.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/roche-and-qualcomm-collaborate-to-innovate-remote-patient-monitoring-300027553.html
SOURCE Qualcomm Incorporated